TNBC is negative for the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2), and therefore does not respond to the targeted therapies that have largely explained the improvements in breast cancer outcomes in recent decades.21, 22. This evidence concerns the gene ESR1 and breast carcinoma.